These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39034670)

  • 1. Quetiapine, Clozapine, and Pimavanserin Treatment Response in Monogenic Parkinson's Disease Psychosis: A Systematic Review.
    Colijn MA
    J Neuropsychiatry Clin Neurosci; 2024 Jul; ():0. PubMed ID: 39034670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease psychosis management: an evidence based, experience informed, pragmatic approach.
    Friedman JH
    Expert Opin Pharmacother; 2024 Feb; 25(2):149-156. PubMed ID: 38344806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
    Majlath Z; Obal I; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical antipsychotics for Parkinson's disease psychosis: a systematic review and meta-analysis.
    Zhang H; Wang L; Fan Y; Yang L; Wen X; Liu Y; Liu Z
    Neuropsychiatr Dis Treat; 2019; 15():2137-2149. PubMed ID: 31551655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy, Safety, and Acceptability of Pimavanserin and Other Atypical Antipsychotics for Parkinson's Disease Psychosis: Systematic Review and Network Meta-Analysis.
    Yunusa I; Rashid N; Seyedin R; Paratane D; Rajagopalan K
    J Geriatr Psychiatry Neurol; 2023 Sep; 36(5):417-432. PubMed ID: 36720473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
    Hubbard D; Hacksell U; McFarland K
    Behav Pharmacol; 2013 Oct; 24(7):628-32. PubMed ID: 23969614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacovigilance assessment of mortality with pimavanserin in Parkinson disease-related psychosis.
    Brown JD; Cicali B; Henriksen C; Malaty I; Okun MS; Armstrong MJ
    J Manag Care Spec Pharm; 2021 Jun; 27(6):785-790. PubMed ID: 34057395
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacological interventions for psychosis in Parkinson's disease patients.
    Friedman JH
    Expert Opin Pharmacother; 2018 Apr; 19(5):499-505. PubMed ID: 29494265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clearing the Fog: A Review of Antipsychotics for Parkinson's-Related Hallucinations: A Focus on Pimavanserin, Quetiapine and Clozapine.
    Abdul-Rahman T; Herrera-Calderón RE; Aderinto N; Kundu M; Wireko AA; Adebusoye FT; Ekerin O; Lawal L; Mykolaivna NI; Alexiou A; Almashjary MN; Perveen A; Ashraf GM
    J Integr Neurosci; 2024 Apr; 23(4):80. PubMed ID: 38682215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis.
    Meltzer HY; Mills R; Revell S; Williams H; Johnson A; Bahr D; Friedman JH
    Neuropsychopharmacology; 2010 Mar; 35(4):881-92. PubMed ID: 19907417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
    Wilby KJ; Johnson EG; Johnson HE; Ensom MHH
    Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
    Duits JH; Ongering MS; Martens HJM; Schulte PFJ
    Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease.
    Menza MM; Palermo B; Mark M
    Ann Clin Psychiatry; 1999 Sep; 11(3):141-4. PubMed ID: 10482124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antipsychotics for the management of psychosis in Parkinson's disease: systematic review and meta-analysis.
    Jethwa KD; Onalaja OA
    BJPsych Open; 2015 Jun; 1(1):27-33. PubMed ID: 27703720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-generation antipsychotics for Parkinson's disease psychosis: A systematic review and network meta-analysis.
    Srisurapanont M; Suradom C; Suttajit S; Kongsaengdao S; Maneeton B
    Gen Hosp Psychiatry; 2024; 87():124-133. PubMed ID: 38412585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hallucinations and delusions associated with Parkinson's disease psychosis: safety of current treatments and future directions.
    Isaacson SH; Citrome L
    Expert Opin Drug Saf; 2022 Jul; 21(7):873-879. PubMed ID: 35466847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of Parkinson's Disease Psychosis.
    Elsibai H; Kualleny M; Fandy TE
    Sr Care Pharm; 2022 Aug; 37(8):339-344. PubMed ID: 35879841
    [No Abstract]   [Full Text] [Related]  

  • 18. Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
    Zahodne LB; Fernandez HH
    Drugs Aging; 2008; 25(8):665-82. PubMed ID: 18665659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pimavanserin and Parkinson's Disease Psychosis: A Narrative Review.
    Rissardo JP; Durante Í; Sharon I; Fornari Caprara AL
    Brain Sci; 2022 Sep; 12(10):. PubMed ID: 36291220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies.
    Horn S; Richardson H; Xie SX; Weintraub D; Dahodwala N
    Parkinsonism Relat Disord; 2019 Dec; 69():119-124. PubMed ID: 31751863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.